McCarthy Lab

Dr. Jason McCarthy creates molecular imaging and drug delivery materials to modulate biology, and visualize biological processes, investigating diseases throughout the body.

News From The McCarthy Lab

McCarthy Publishes Breakthrough Study

Dr. McCarthy was recognized for his breakthrough study detailing a novel approach to minimize damage after a heart attack which was published in the prestigious scientific journal, Advanced Materials.

Areas of Investigation

Dr. McCarthy’s research aims to integrate molecular imaging techniques and novel drug delivery methods to study and treat a variety of diseases.

Molecular Imaging: A tool that allows the visualization of biological processes occurring in the body. Dr. McCarthy specifically uses fluorescent imaging via fluorogenic and targeted imaging probes.

Drug Delivery: Dr. McCarthy generates materials that can target drugs to specific cells within the body. Current platforms can deliver small molecules or oligonucleotides such as mRNA, to the sites of action.

Lab Focus

Play Video

Materials for the Modulation of Biology

medical testing by techs

Dr. McCarthy focuses on making simple materials with the potential to treat complex diseases. This is accomplished by specifically targeting the cells responsible for the initiation and progression of disease with nanometer-sized particles loaded with therapeutics.  To achieve this goal, his group designs systems incorporating polymers and lipids capable of encapsulating drugs.  These nanoparticles are then modified with peptide-based ligands adept at recognizing specific targets on cell surfaces or within the extracellular matrix.  These materials are being investigated in a number of diseases, including myocardial infarction, pulmonary fibrosis, systemic lupus erythematosius, and transplant rejection.

Visualizing Biological Processes

To detect the interplay of processes that occur in disease, fluorescent agents are generated which are either activated by enzymes (fluorogenic) or bind to targets of interest to allow their investigation in both a non-invasive and longitudinal manner.  For the fluorescent probes, target recognition sequences for receptors or matrices of interest are used to rapidly generate peptides via a microwave-assisted synthesis and subsequently labeled with fluorophores to enable in vivo detection.  Similarly, the fluorogenic probes are derived from peptide sequences recognized by enzymes of interest and labeled with fluorescent dyes, but are appended to polymeric backbones, enabling fluorescence turn-on upon interaction with the appropriate enzyme.  These imaging agents are routinely used to probe matrix deposition (collagen, fibrin, hydroxyapatite), receptor status (somatostatin, cell adhesion molecules, integrins) and enzyme activity (plasmin, thrombin, granzyme B).

pouring liquid into a beaker

Investigation of Diseases

McCarthy Lab looking at a solution

Our technologies are developed in collaboration with investigators across the globe to enable breakthroughs that will change the future of medicine. Current work focuses on:

  • Atherosclerosis
  • Alzheimer’s disease
  • Bone regeneration
  • Diabetes
  • Fibrosis
  • Myocardial infarction
  • Heart failure
  • Ischemia
  • Lupus nephritis
  • Osteosarcoma
  • Pneumonia
  • Systemic lupus erythematosus
  • Thrombosis and pulmonary embolism
  • Polytrauma
  • Transplant rejection
jason McCarthy headshot

Meet Dr. Jason McCarthy

Scientific Operations Director
Associate Professor / Biomedical Research and Translational Medicine

jmccarthy@mmri.edu

Dr. McCarthy holds his bachelor’s degree in chemistry from Western New England College, Springfield, Massachusetts. Dr. McCarthy continued his studies at the University of Connecticut, Storrs, Connecticut, under the tutelage of Dr. Christian Brückner, focusing on the modification of porphyrinic chromophores. This work led to the discovery of previously unknown ring-fused chlorins and indaphyrins with unexpected photophysical properties.

Upon the completion of his doctorate in inorganic chemistry in 2003, Dr. McCarthy joined the Center for Molecular Imaging Research (CMIR) at the Massachusetts General Hospital (MGH), Cambridge, Massachusetts, as a Ruth L. Kirschstein Institutional National Research Service Award T32 postdoctoral fellow under the direction of Dr. Ralph Weissleder. At the CMIR he was trained in nanomedicine and its application to biological systems, in addition to the molecular imaging that was the mainstay of the Center. In 2006, Dr. McCarthy was appointed as an instructor in radiology at Harvard Medical School and established his research group, which subsequently moved to the Center for Systems Biology at the MGH in 2007, where he was promoted to assistant professor of radiology in 2010.

Over the past decade, the research focus of his group has become much more diverse, including the generation of imaging agents for the detection of molecular processes in the in vivo environment, and the delivery of drug moieties in a cell-specific manner. The multidisciplinary nature of this research led Dr. McCarthy to the Masonic Medical Research Institute in 2018 as an associate professor of biomedical research and translational medicine and the scientific operations director, where his group aims to push the boundaries of nanomedicine, potentiating novel treatment options for an untold number of diseases.

Lab Members

Khanh Ha headshot

Khanh Ha, Ph.D.

Instructor

Ha holds a bachelor’s degree in chemical engineering from Irkutsk State Technical University, Russia and a PhD in chemistry with a minor in pharmaceutical science from the University of Florida, Gainesville, Florida. Ha has more than eight years of experience in molecular imaging and targeted drug delivery.

Vikas Sharma headshot for web

Vikas Sharma, Ph.D.

Postdoctoral Fellow

Sharma holds a PhD from the Indian Institute of Technology Banaras Hindu University, Varanasi, Uttar Pradesh, where he studied under Dr. M.S. Muthu. Vikas has experience in pharmaceutics and focuses on the generation of nanomaterials for targeted drug delivery.

Justin headshot

Justin Jablonski

Research Associate

Jablonski has both a master's and bachelor’s in Biomedical Engineering from the University of Rochester, Rochester, New York. Jablonski's role in Dr. McCarthy’s lab will focus on conducting materials validation, through in vitro and in vivo investigation.

Portrait of Maddelyn Hoehn

Maddelyn Hoehn

Research Assistant

Hoehn holds a bachelor's degree in biology with a minor in chemistry from SUNY Polytechnic Institute, Utica, New York. Hoehn assists with the synthesis of fluorescent dyes and various fluorescent probes.

2025 Summer Fellows

  • Lucas Constantine
  • Nurhaliza Syukur

Past Lab Members

Jayeeta Bhaumik, Ph.D., 2007-2010
Pouneh Haghayeghi, 2007
Sibel Erdem, Ph.D., 2009-2012
Kevin Bardon, Ph.D., 2009-2013
Yali Li, Ph.D., 2010-2012
Michael Daly, 2010
MD Nurrunabi, Ph.D., 2016-2018
Muthunarayanan Muthiah, Ph.D., 2016-2020
Vanessa Bang, 2016
Chase Kessinger, Ph.D., 2018-2022
Elijah Marris, Ph.D., 2018
Alayna Trice, 2018
Rajendran Bose, Ph.D., 2019-2022
Sa Lay Wah, 2019
Khada Nagi, 2019
Donna Le, 2019
Katherine Jankowski, 2021
Vaea Salt-Bernard, 2021
Catherine Hagearty-Mattern, 2021-2023
Jeffrey Cheng, 2021-2023
Zackary Caporale, 2022-2023
Dasomie Kim, 2023
Yuriy Milobog, 2022-2025
Hope Garramone, Summer 2024
Alinur Jaboldinov, Summer 2024
Julie Sassower, Summer 2024

Publications

  1. Ikegami, R, Piao, Z, Iglesias, JF, Pilgrim, T, Ha, K, McCarthy, JR et al.. Ultrathin-strut versus thin-strut stent healing and outcomes in preclinical and clinical subjects. EuroIntervention. 2024;20 (10):e669-e680. doi: 10.4244/EIJ-D-23-00563. PubMed PMID:38776143 PubMed Central PMC11100507.
  2. Bose, RJ, Kessinger, CW, Dhammu, T, Singh, T, Shealy, MW, Ha, K et al.. Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Postmyocardial Infarction. Adv Mater. 2024;36 (8):e2304615. doi: 10.1002/adma.202304615. PubMed PMID:37934471 PubMed Central PMC10922695.
  3. Knipe, RS, Nurunnabi, M, Probst, CK, Spinney, JJ, Abe, E, Bose, RJC et al.. Myofibroblast-specific inhibition of the Rho kinase-MRTF-SRF pathway using nanotechnology for the prevention of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2023;324 (2):L190-L198. doi: 10.1152/ajplung.00086.2022. PubMed PMID:36625494 PubMed Central PMC9925159.
  4. Bose, RJ, Kumar, US, Garcia-Marques, F, Zeng, Y, Habte, F, McCarthy, JR et al.. Engineered Cell-Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple-Negative Breast Cancer in Mice. Adv Healthc Mater. 2022;11 (5):e2101387. doi: 10.1002/adhm.202101387. PubMed PMID:34879180 PubMed Central PMC8891081.
  5. Saito, M, Moore-Lotridge, SN, Uppuganti, S, Egawa, S, Yoshii, T, Robinette, JP et al.. Determining the pharmacologic window of bisphosphonates that mitigates severe injury-induced osteoporosis and muscle calcification, while preserving fracture repair. Osteoporos Int. 2022;33 (4):807-820. doi: 10.1007/s00198-021-06208-7. PubMed PMID:34719727 PubMed Central PMC9530779.
  6. Ha, K, Zheng, X, Kessinger, CW, Mauskapf, A, Li, W, Kawamura, Y et al.. In Vivo Platelet Detection Using a Glycoprotein IIb/IIIa-Targeted Near-Infrared Fluorescence Imaging Probe. ACS Sens. 2021;6 (6):2225-2232. doi: 10.1021/acssensors.1c00124. PubMed PMID:34056903 PubMed Central PMC8767556.
  7. Bose, RJ, Ha, K, McCarthy, JR. Bio-inspired nanomaterials as novel options for the treatment of cardiovascular disease. Drug Discov Today. 2021;26 (5):1200-1211. doi: 10.1016/j.drudis.2021.01.035. PubMed PMID:33561512 PubMed Central PMC8205945.
  8. Loo, YS, Bose, RJ, McCarthy, JR, Mat Azmi, ID, Madheswaran, T. Biomimetic bacterial and viral-based nanovesicles for drug delivery, theranostics, and vaccine applications. Drug Discov Today. 2021;26 (4):902-915. doi: 10.1016/j.drudis.2020.12.017. PubMed PMID:33383213 .
  9. Bose, RJC, Tharmalingam, N, Choi, Y, Madheswaran, T, Paulmurugan, R, McCarthy, JR et al.. Combating Intracellular Pathogens with Nanohybrid-Facilitated Antibiotic Delivery. Int J Nanomedicine. 2020;15 :8437-8449. doi: 10.2147/IJN.S271850. PubMed PMID:33162754 PubMed Central PMC7642590.
  10. Unudurthi, SD, Luthra, P, Bose, RJC, McCarthy, JR, Kontaridis, MI. Cardiac inflammation in COVID-19: Lessons from heart failure. Life Sci. 2020;260 :118482. doi: 10.1016/j.lfs.2020.118482. PubMed PMID:32971105 PubMed Central PMC7505073.
  11. Bose, RJC, McCarthy, JR. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19. Drug Discov Today. 2020;25 (9):1559-1560. doi: 10.1016/j.drudis.2020.06.021. PubMed PMID:32592868 PubMed Central PMC7313487.
  12. Jing, JLJ, Pei Yi, T, Bose, RJC, McCarthy, JR, Tharmalingam, N, Madheswaran, T et al.. Hand Sanitizers: A Review on Formulation Aspects, Adverse Effects, and Regulations. Int J Environ Res Public Health. 2020;17 (9):. doi: 10.3390/ijerph17093326. PubMed PMID:32403261 PubMed Central PMC7246736.
  13. Bose, RJC, Tharmalingam, N, Garcia Marques, FJ, Sukumar, UK, Natarajan, A, Zeng, Y et al.. Reconstructed Apoptotic Bodies as Targeted "Nano Decoys" to Treat Intracellular Bacterial Infections within Macrophages and Cancer Cells. ACS Nano. 2020;14 (5):5818-5835. doi: 10.1021/acsnano.0c00921. PubMed PMID:32347709 PubMed Central PMC9116903.
  14. Cui, J, Kessinger, CW, Jhajj, HS, Grau, MS, Misra, S, Libby, P et al.. Atorvastatin Reduces In Vivo Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula. J Am Soc Nephrol. 2020;31 (5):931-945. doi: 10.1681/ASN.2019060612. PubMed PMID:32152232 PubMed Central PMC7217409.
  15. Baker, CE, Moore-Lotridge, SN, Hysong, AA, Posey, SL, Robinette, JP, Blum, DM et al.. Bone Fracture Acute Phase Response-A Unifying Theory of Fracture Repair: Clinical and Scientific Implications. Clin Rev Bone Miner Metab. 2018;16 (4):142-158. doi: 10.1007/s12018-018-9256-x. PubMed PMID:30930699 PubMed Central PMC6404386.
  16. Stein-Merlob, AF, Hara, T, McCarthy, JR, Mauskapf, A, Hamilton, JA, Ntziachristos, V et al.. Atheroma Susceptible to Thrombosis Exhibit Impaired Endothelial Permeability In Vivo as Assessed by Nanoparticle-Based Fluorescence Molecular Imaging. Circ Cardiovasc Imaging. 2017;10 (5):. doi: 10.1161/CIRCIMAGING.116.005813. PubMed PMID:28487316 PubMed Central PMC5509162.
  17. Bozhko, D, Osborn, EA, Rosenthal, A, Verjans, JW, Hara, T, Kellnberger, S et al.. Quantitative intravascular biological fluorescence-ultrasound imaging of coronary and peripheral arteries in vivo. Eur Heart J Cardiovasc Imaging. 2017;18 (11):1253-1261. doi: 10.1093/ehjci/jew222. PubMed PMID:28031233 PubMed Central PMC5837649.
  18. Hara, T, Ughi, GJ, McCarthy, JR, Erdem, SS, Mauskapf, A, Lyon, SC et al.. Intravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivo. Eur Heart J. 2017;38 (6):447-455. doi: 10.1093/eurheartj/ehv677. PubMed PMID:26685129 PubMed Central PMC5837565.
  19. Stein-Merlob, AF, Kessinger, CW, Erdem, SS, Zelada, H, Hilderbrand, SA, Lin, CP et al.. Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study. Theranostics. 2015;5 (12):1317-27. doi: 10.7150/thno.12494. PubMed PMID:26516370 PubMed Central PMC4615735.
  20. Konishi, M, Erdem, SS, Weissleder, R, Lichtman, AH, McCarthy, JR, Libby, P et al.. Imaging Granzyme B Activity Assesses Immune-Mediated Myocarditis. Circ Res. 2015;117 (6):502-512. doi: 10.1161/CIRCRESAHA.115.306364. PubMed PMID:26199323 PubMed Central PMC4553143.
  21. Kessinger, CW, Kim, JW, Henke, PK, Thompson, B, McCarthy, JR, Hara, T et al.. Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring. PLoS One. 2015;10 (2):e0116621. doi: 10.1371/journal.pone.0116621. PubMed PMID:25680183 PubMed Central PMC4334538.
  22. Cui, J, Kessinger, CW, McCarthy, JR, Sosnovik, DE, Libby, P, Thadhani, RI et al.. In vivo nanoparticle assessment of pathological endothelium predicts the development of inflow stenosis in murine arteriovenous fistula. Arterioscler Thromb Vasc Biol. 2015;35 (1):189-96. doi: 10.1161/ATVBAHA.114.304483. PubMed PMID:25395614 PubMed Central PMC4270948.
  23. Lauriol, J, Keith, K, Jaffré, F, Couvillon, A, Saci, A, Goonasekera, SA et al.. RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis. Sci Signal. 2014;7 (348):ra100. doi: 10.1126/scisignal.2005262. PubMed PMID:25336613 PubMed Central PMC4300109.
  24. Saxena, A, Kessinger, CW, Thompson, B, McCarthy, JR, Iwamoto, Y, Lin, CP et al.. High-resolution optical mapping of inflammatory macrophages following endovascular arterial injury. Mol Imaging Biol. 2013;15 (3):282-9. doi: 10.1007/s11307-012-0599-2. PubMed PMID:23090852 PubMed Central PMC3650124.
  25. Ripplinger, CM, Kessinger, CW, Li, C, Kim, JW, McCarthy, JR, Weissleder, R et al.. Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2012;32 (11):2616-24. doi: 10.1161/ATVBAHA.112.251983. PubMed PMID:22995524 PubMed Central PMC3516622.
  26. Brückner, C, Ogikubo, J, McCarthy, JR, Akhigbe, J, Hyland, MA, Daddario, P et al.. meso-arylporpholactones and their reduction products. J Org Chem. 2012;77 (15):6480-94. doi: 10.1021/jo300963m. PubMed PMID:22734444 PubMed Central PMC3411881.
  27. Hara, T, Bhayana, B, Thompson, B, Kessinger, CW, Khatri, A, McCarthy, JR et al.. Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence. JACC Cardiovasc Imaging. 2012;5 (6):607-15. doi: 10.1016/j.jcmg.2012.01.017. PubMed PMID:22698530 PubMed Central PMC3376390.
  28. Erdem, SS, Sazonova, IY, Hara, T, Jaffer, FA, McCarthy, JR. Detection and treatment of intravascular thrombi with magnetofluorescent nanoparticles. Methods Enzymol. 2012;508 :191-209. doi: 10.1016/B978-0-12-391860-4.00010-0. PubMed PMID:22449927 .
  29. McCarthy, JR, Sazonova, IY, Erdem, SS, Hara, T, Thompson, BD, Patel, P et al.. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy. Nanomedicine (Lond). 2012;7 (7):1017-28. doi: 10.2217/nnm.11.179. PubMed PMID:22348271 PubMed Central PMC3360120.
  30. Ghosh, K, Kanapathipillai, M, Korin, N, McCarthy, JR, Ingber, DE. Polymeric nanomaterials for islet targeting and immunotherapeutic delivery. Nano Lett. 2012;12 (1):203-8. doi: 10.1021/nl203334c. PubMed PMID:22196766 PubMed Central PMC3280082.
  31. Yoo, H, Kim, JW, Shishkov, M, Namati, E, Morse, T, Shubochkin, R et al.. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011;17 (12):1680-4. doi: 10.1038/nm.2555. PubMed PMID:22057345 PubMed Central PMC3233646.
  32. Brückner, C, Götz, DC, Fox, SP, Ryppa, C, McCarthy, JR, Bruhn, T et al.. Helimeric porphyrinoids: stereostructure and chiral resolution of meso-tetraarylmorpholinochlorins. J Am Chem Soc. 2011;133 (22):8740-52. doi: 10.1021/ja202451t. PubMed PMID:21534626 .
  33. McCarthy, JR, Bhaumik, J, Karver, MR, Sibel Erdem, S, Weissleder, R. Targeted nanoagents for the detection of cancers. Mol Oncol. 2010;4 (6):511-28. doi: 10.1016/j.molonc.2010.08.003. PubMed PMID:20851695 PubMed Central PMC2981649.
  34. McCarthy, JR, Korngold, E, Weissleder, R, Jaffer, FA. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small. 2010;6 (18):2041-9. doi: 10.1002/smll.201000596. PubMed PMID:20721949 PubMed Central PMC3018665.
  35. Chang, K, Francis, SA, Aikawa, E, Figueiredo, JL, Kohler, RH, McCarthy, JR et al.. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2010;30 (10):1933-9. doi: 10.1161/ATVBAHA.110.206342. PubMed PMID:20689078 PubMed Central PMC3030475.
  36. McCarthy, JR. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv Drug Deliv Rev. 2010;62 (11):1023-30. doi: 10.1016/j.addr.2010.07.004. PubMed PMID:20654664 PubMed Central PMC2974776.
  37. McCarthy, JR. Nanomedicine and Cardiovascular Disease. Curr Cardiovasc Imaging Rep. 2010;3 (1):42-49. doi: 10.1007/s12410-009-9002-3. PubMed PMID:20369034 PubMed Central PMC2848940.
  38. Panizzi, P, Nahrendorf, M, Wildgruber, M, Waterman, P, Figueiredo, JL, Aikawa, E et al.. Oxazine conjugated nanoparticle detects in vivo hypochlorous acid and peroxynitrite generation. J Am Chem Soc. 2009;131 (43):15739-44. doi: 10.1021/ja903922u. PubMed PMID:19817443 PubMed Central PMC2773134.
  39. McCarthy, JR, Bhaumik, J, Merbouh, N, Weissleder, R. High-yielding syntheses of hydrophilic conjugatable chlorins and bacteriochlorins. Org Biomol Chem. 2009;7 (17):3430-6. doi: 10.1039/b908713c. PubMed PMID:19675897 PubMed Central PMC2749955.
  40. Bhaumik, J, Weissleder, R, McCarthy, JR. Synthesis and photophysical properties of sulfonamidophenyl porphyrins as models for activatable photosensitizers. J Org Chem. 2009;74 (16):5894-901. doi: 10.1021/jo900832y. PubMed PMID:19610602 PubMed Central PMC2888918.
  41. McCarthy, JR, Patel, P, Botnaru, I, Haghayeghi, P, Weissleder, R, Jaffer, FA et al.. Multimodal nanoagents for the detection of intravascular thrombi. Bioconjug Chem. 2009;20 (6):1251-5. doi: 10.1021/bc9001163. PubMed PMID:19456115 PubMed Central PMC2733224.
  42. McCarthy, JR, Weissleder, R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60 (11):1241-1251. doi: 10.1016/j.addr.2008.03.014. PubMed PMID:18508157 PubMed Central PMC2583936.
  43. McCarthy, JR, Kelly, KA, Sun, EY, Weissleder, R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond). 2007;2 (2):153-67. doi: 10.2217/17435889.2.2.153. PubMed PMID:17716118 .
  44. Kelly, KA, Carson, J, McCarthy, JR, Weissleder, R. Novel peptide sequence ("IQ-tag") with high affinity for NIR fluorochromes allows protein and cell specific labeling for in vivo imaging. PLoS One. 2007;2 (7):e665. doi: 10.1371/journal.pone.0000665. PubMed PMID:17653285 PubMed Central PMC1919420.
  45. McCarthy, JR, Weissleder, R. Model systems for fluorescence and singlet oxygen quenching by metalloporphyrins. ChemMedChem. 2007;2 (3):360-5. doi: 10.1002/cmdc.200600244. PubMed PMID:17245681 .
  46. McCarthy, JR, Jaffer, FA, Weissleder, R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small. 2006;2 (8-9):983-7. doi: 10.1002/smll.200600139. PubMed PMID:17193154 .
  47. Choi, Y, McCarthy, JR, Weissleder, R, Tung, CH. Conjugation of a photosensitizer to an oligoarginine-based cell-penetrating peptide increases the efficacy of photodynamic therapy. ChemMedChem. 2006;1 (4):458-63. doi: 10.1002/cmdc.200500036. PubMed PMID:16892381 .
  48. McCarthy, JR, Perez, JM, Brückner, C, Weissleder, R. Polymeric nanoparticle preparation that eradicates tumors. Nano Lett. 2005;5 (12):2552-6. doi: 10.1021/nl0519229. PubMed PMID:16351214 .
  49. McCarthy, JR, Hyland, MA, Brückner, C. Synthesis of indaphyrins: meso-tetraarylsecochlorin-based porphyrinoids containing direct o-phenyl-to-beta-linkages. Org Biomol Chem. 2004;2 (10):1484-91. doi: 10.1039/b401629g. PubMed PMID:15136804 .
  50. McCarthy, JR, Jenkins, HA, Brückner, C. Free base meso-tetraaryl-morpholinochlorins and porpholactone from meso-tetraaryl-2,3-dihydroxy-chlorin. Org Lett. 2003;5 (1):19-22. doi: 10.1021/ol027072a. PubMed PMID:12509880 .
Search PubMed

Chase Kessinger, Ph.D.

Chase Kessinger, Ph.D.

Thank You

Make a Donation, Make a Difference

“We’re generating tomorrow’s therapeutics and revolutionizing how patients are treated for disease,” said Dr. McCarthy.

Consider donating to further the research of Dr. McCarthy and his laboratory.

DONATE NOW
green half circle